Nadal, Ernest
Saleh, Mansoor
Aix, Santiago Ponce
Ochoa-de-Olza, Maria
Patel, Sandip Pravin
Antonia, Scott
Zhao, Yumin
Gueorguieva, Ivelina
Man, Michael
Estrem, Shawn T.
Liu, Jiangang
Avsar, Emin
Lin, Wen Hong
Benhadji, Karim A.
Gandhi, Leena
Guba, Susan C.
Diaz, Inmaculada Ales
Funding for this research was provided by:
Eli Lilly and Company
Bristol-Myers Squibb
Article History
Received: 26 October 2022
Accepted: 5 July 2023
First Online: 28 July 2023
Declarations
:
: The protocol was approved by University of Texas MD Anderson Cancer Center, Western Institutional Review Board WIRB, Dana Farber Cancer Institute, Chesapeake Research Review Inc, University of California San Diego, and Hospital Universitari Vall d’Hebron. Local ethical review boards and all methods were conducted according to the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. Informed consent was obtained from all the participants.
: Not required.
: This work was supported by Eli Lilly and Company. S. Estrem, I. Gueorguieva, M. Man, and J. Liu are full time employees and minor stockholders of Eli Lilly and Company. L. Ghandi was a full time employee of Eli Lilly and Company at the time of this work and is minor stockholder of Eli Lilly and Company, has received consultancy fees from Pilant Therapeutics, 28–7 Therapeutics, Riva Therapeutics, and Eli Lilly and company, has received speaker's bureau honoraria from Tempus, is on the advisory board for Beigene, Bristol-Myers Squibb, Mersana, Eisai, Xilio, and Tentarix, and is on the board of directors for Bright Peak Therapeutics an Neximmune. Y. Zhao, and S. Guba were full time employees and minor stockholders of Eli Lilly and Company at the time of this work. S. Guba has also received medical writing support from Eli Lilly and Company. K.A. Benhadji owns a patent with and is a minor stockholder of Eli Lilly and Company. E. Avsar is a full time employee of Eli Lilly and Company and a minor stockholder in Eli Lilly and Company and BMS, and was a full time employee of BMS at the time of this work. W. H Lin was an employee of BMS when this work was performed. E. Nadal has received grants or research funding from Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, and Merck Serono, and has received speaker's bureau honoraria from Roche, Bristol Myers Squibb, Merck Sharp Dohme, Merck-Serono, Sanofi, Pfizer, Eli Lilly, Amgen, Boehringer-Ingelheim, AstraZeneca, Takeda, Sanofi, Janssen, Qiagen and Bayer. S. Patel is an advisory board member for Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly and Company, Jazz, Genentech, Illumina, Merck, Pfizer, Rakuten, and Tempus. S. Patel's university receives research funding from Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly and Company, Fate Therapeutics, Iovance, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies. M. Saleh received medical writing support from Eli Lilly and Company. S. Antonia has been a consultant or advisory board member for Achilles Therapeutics, Amgen, Bristol-Myers Squibb, Celsius Therapeutics, G1 Therapeutics, Glimpse, Guardian Bio, GSK, Immutep, Memgen, Merck, RAPT Therapeutics, Shoreline, Taurus, Xilis, has been on the data safety monitoring board for EMD Serano, is a stockowner of Guardian, Shoreline, and RAPT Therapeutics, and has received travel reimbursement from RAPT Therapeutics. I. Ales Diaz, M. Ochoa-de-Olza, and S. Ponce Aix have nothing to declare.